Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase

British Journal of Pharmacology

Volumn 153, Issue 5, 2008, Pages 983-991

  Whittle, B J R ^a   Varga, C ^b   Berko, A ^b   Horvath, K ^b   Posa, A ^b   Riley, J P ^c   Lundeen, K A ^c   Fourie, A M ^c   Dunford, P J ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SZEGED   (Hungary)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

5 lipoxygenase; Colitis; Inflammatory bowel disease; Interleukin 6; JNJ 26993135; Tumour necrosis factor ; Zileuton

Indexed keywords

1 [4 (BENZOTHIAZOL 2 YLOXY)BENZYL] PIPERIDINE 4 CARBOXYLIC ACID; INTERLEUKIN 6; JNJ 26993135; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 40149104966     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707645     Document Type: Article

References (65)

1. Askonas LJ, Kachur JF, Villani‐Price D, Liang CD, Russell MA, Smith WG (2002). Pharmacological characterization of SC‐57461A (3‐[methyl[3‐[4‐(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies. J Pharmacol Exp Ther 300: 577–582.
2. Beierschmitt WP, McNeish JD, Griffiths RJ, Nagahisa A, Nakane M, Amacher DE (2001). Induction of hepatic microsomal drug‐metabolizing enzymes by inhibitors of 5‐lipoxygenase (5‐LO): studies in rats and 5‐LO knockout mice. Toxicol Sci 63: 15–21.
3. Bertran X, Mane J, Fernandez‐Banares F, Castella E, Bartoli R, Ojanguren I et al. (1996). Intracolonic administration of zileuton, a selective 5‐lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis. Gut 38: 899–904.
4. Boughton‐Smith NK, Hawkey CJ, Whittle BJR (1983). Biosynthesis of lipoxygenase and cyclo‐oxygenase products from [14C]‐arachidonic acid by human colonic mucosa. Gut 24: 1176–1182.
5. Boughton‐Smith NK, Wallace JL, Morris GP, Whittle BJR (1988a). The effect of anti‐inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br J Pharmacol 94: 65–72.
6. Boughton‐Smith NK, Wallace J, Whittle BJR (1988b). Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions 25: 115–123.
7. Camuesco D, Comalada M, Rodriguez‐Cabezas ME, Nieto A, Lorente MD, Concha A et al. (2004). The intestinal anti‐inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol 143: 908–918.
8. Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G, Reyes E et al. (1992). Phase II study of the safety and efficacy of a 5‐lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol 87: 342–346.
9. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE et al. (2006). The lipoxin receptor ALX: potent ligand‐specific and stereoselective actions in vivo. Pharmacol Rev 58: 463–487.
10. Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S et al. (2004). A beta‐oxidation‐resistant lipoxin A4 analog treats hapten‐induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA 101: 15736–15741.
11. Ford‐Hutchinson AW, Gresser M, Young RN (1994). 5‐Lipoxygenase. Annu Rev Biochem 63: 383–417.
12. Funk CD (2005). Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4: 664–672.
13. Gagnon L, Filion LG, Dubois C, Rola‐Pleszczynski M (1989). Leukotrienes and macrophage activation: augmented cytotoxic activity and enhanced interleukin 1, tumor necrosis factor and hydrogen peroxide production. Agents Actions 26: 141–147.
14. Gewirtz AT, Collier‐Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF et al. (2002). Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate‐induced colitis. J Immunol 168: 5260–5267.
15. Gonzalez R, de Medina FS, Martinez‐Augustin O, Nieto A, Galvez J, Risco S et al. (2004). Anti‐inflammatory effect of diosmectite in hapten‐induced colitis in the rat. Br J Pharmacol 141: 951–960.
16. Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J et al. (2005). Profile of soluble cytokine receptors in Crohn's disease. Gut 54: 488–495.
17. Haeggstrom JZ (2004). Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol Chem 279: 50639–50642.
18. Hart AL, Al‐Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC et al. (2005). Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129: 50–65.
19. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF (1997). A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 112: 718–724.
20. Hawthorne AB, Boughton‐Smith NK, Whittle BJR, Hawkey CJ (1992). Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5‐lipoxygenase inhibitor BWA4C. Gut 33: 513–517.
21. Hogan SP, Rothenberg ME (2004). The eosinophil as a therapeutic target in gastrointestinal disease. Aliment Pharmacol Ther 20: 1231–1240.
22. Holma R, Salmenpera P, Riutta A, Virtanen I, Korpela R, Vapaatalo H (2001). Acute effects of the cys‐leukotriene‐1 receptor antagonist, montelukast, on experimental colitis in rats. Eur J Pharmacol 429: 309–318.
23. Ito H (2004). Novel therapy for Crohn's disease targeting IL‐6 signalling. Expert Opin Ther Targets 8: 287–294.
24. Jupp J, Hillier K, Elliott DH, Fine DR, Bateman AC, Johnson PA et al. (2007). Colonic expression of leukotriene‐pathway enzymes in inflammatory bowel diseases. Inflamm Bowel Dis 13: 537–546.
25. Kachur JF, Askonas LJ, Villani‐Price D, Ghoreishi‐Haack N, Won‐Kim S, Liang CD et al. (2002). Pharmacological characterization of SC‐57461A (3‐[methyl[3‐[4‐(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. J Pharmacol Exp Ther 300: 583–587.
26. Kitamura K, Nakamoto Y, Kaneko S, Mukaida N (2004). Pivotal roles of interleukin‐6 in transmural inflammation in murine T cell transfer colitis. J Leukoc Biol 76: 1111–1117.
27. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R (2004). Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 53: 1806–1812.
28. Lobos EA, Sharon P, Stenson WF (1987). Chemotactic activity in inflammatory bowel disease. Role of leukotriene B 4. Dig Dis Sci 32: 1380–1388.
29. Mangino MJ, Brounts L, Harms B, Heise C (2006). Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat 79: 84–92.
30. Maric I, Poljak L, Zoricic S, Bobinac D, Bosukonda D, Sampath KT et al. (2003). Bone morphogenetic protein‐7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol 196: 258–264.
31. Morris GP, Beck PL, Herridge MS, Depew WT, Szewzcuk MR, Wallace JL (1989). Hapten‐induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795–803.
32. Muller S, Lory J, Corazza N, Griffiths GM, Z'graggen K, Mazzucchelli L et al. (1998). Activated CD4+ and CD8+ cytotoxic T cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am J Pathol 152: 261–268.
33. Murray J, Ward C, O'Flaherty JT, Dransfield I, Haslett C, Chilvers ER et al. (2003). Role of leukotrienes in the regulation of human granulocyte behaviour: dissociation between agonist‐induced activation and retardation of apoptosis. Br J Pharmacol 139: 388–398.
34. Nancey S, Holvoet S, Graber I, Joubert G, Philippe D, Martin S et al. (2006). CD8+ cytotoxic T cells induce relapsing colitis in normal mice. Gastroenterology 131: 485–496.
35. Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ (2003). Mast cell‐dependent migration of effector CD8+ T cells through production of leukotriene B 4. Nat Immunol 4: 974–981.
36. Penning TD (2001). Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti‐inflammatory agents. Curr Pharm Des 7: 163–179.
37. Penning TD, Chandrakumar NS, Desai BN, Djuric SW, Gasiecki AF, Malecha JW et al. (2003). Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem Lett 13: 1137–1139.
38. Penning TD, Russell MA, Chen BB, Chen HY, Liang CD, Mahoney MW et al. (2002). Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3‐[methyl[3‐[4‐phenylmethyl) phenoxy] propyl] amino] propanoic acid. J Med Chem 45: 3482–3490.
39. Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD, Wasserman MA (1989). Inflammatory mediators of experimental colitis in rats. Gastroenterology 97: 326–337.
40. Raddatz D, Bockemuhl M, Ramadori G (2005). Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17: 547–557.
41. Rao N, Dunford PJ, Xue X, Lundeen KA, Coles F, Riley JP et al. (2007). Anti‐inflammatory activity of a potent, selective leukotriene A 4 hydrolase inhibitor, in comparison to the 5‐lipoxygenase inhibitor, zileuton. J Pharmacol Exp Ther 321: 1154–1160.
42. Rask‐Madsen J, Bukhave K, Laursen LS, Lauritsen K (1992). 5‐Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions. Spec No:C37–46.
43. Rivera E, Flores I, Rivera E, Appleyard CB (2006). Molecular profiling of a rat model of colitis: validation of known inflammatory genes and identification of novel disease‐associated targets. Inflamm Bowel Dis 12: 950–966.
44. Roberts WG, Simon TJ, Berlin RG, Haggitt RC, Snyder ES, Stenson WF et al. (1997). Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK‐591. Gastroenterology 112: 725–732.
45. Rudberg PC, Tholander F, Andberg M, Thunnissen MM, Haeggstrom JZ (2004). Leukotriene A 4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates. J Biol Chem 279: 27376–27382.
46. Rutgeerts P, Van Assche G, Vermeire S (2006). Review article: Infliximab therapy for inflammatory bowel disease ‐seven years on. Aliment Pharmacol Ther 23: 451–463.
47. Sharon P, Stenson WF (1984). Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86: 453–460.
48. Shin EH, Lee HY, Bae YS (2006). Leukotriene B 4 stimulates human monocyte‐derived dendritic cell chemotaxis. Biochem Biophys Res Commun 348: 606–611.
49. Serhan CN, Savill J (2005). Resolution of inflammation: the beginning programs the end. Nat Immunol 6: 1191–1197.
50. Stankova J, Dupuis G, Gagnon N, Thivierge M, Turcotte S, Rola‐Pleszczynski M (1993). Priming of human monocytes with leukotriene B4 enhances their sensitivity in IL‐2 driven tumor necrosis factor‐alpha production. Transcriptional and post‐transcriptional upregulation of IL‐2 receptors. J Immunol 150: 4041–4051.
51. Sun FF, Lai PS, Yue G, Yin K, Nagele RG, Tong DM et al. (2001). Pattern of cytokine and adhesion molecule mRNA in hapten‐induced relapsing colon inflammation in the rat. Inflammation 25: 33–45.
52. Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME et al. (1999). The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 13: 1535–1542.
53. Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB et al. (2003). Leukotriene B 4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 4: 982–990.
54. Takeshita K, Sakai K, Bacon KB, Gantner F (2003). Critical role of histamine H4 receptor in leukotriene B4 production and mast cell‐dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther 307: 1072–1078.
55. Ten Hove T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P et al. (2001). Blockade of endogenous IL‐18 ameliorates TNBS‐induced colitis by decreasing local TNF‐alpha production in mice. Gastroenterology 121: 1372–1379.
56. Thivierge M, Rola‐Pleszczynski M (1992). Platelet‐activating factor enhances interleukin‐6 production by alveolar macrophages. J Allergy Clin Immunol 90: 796–802.
57. Torres MI, Garcia‐Martin M, Fernandez MI, Nieto N, Gil A, Rios A (1999). Experimental colitis induced by trinitrobenzenesulfonic acid: an ultrastructural and histochemical study. Dig Dis Sci 44: 2523–2529.
58. Varga C, Horvath K, Berko A, Thurmond RL, Dunford PJ, Whittle BJR (2005). Inhibitory effects of histamine H 4 receptor antagonists on experimental colitis in the rat. Eur J Pharmacol 522: 130–138.
59. Villegas I, La Casa C, Orjales A, Alarcon de la Lastra C (2003). Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid‐induced colitis in rats. Eur J Pharmacol 460: 209–218.
60. Wallace JL, Keenan CM (1990). An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 258: G527–G534.
61. Werz O, Steinhilber D (2006). Therapeutic options for 5‐lipoxygenase inhibitors. Pharmacol Ther 112: 701–718.
62. Whittle BJR, Cavicchi M, Lamarque D (2003). Assessment of anticolitic drugs in the trinitrobenzene sulfonic acid (TNBS) rat model of inflammatory bowel disease. In: Winyard PG, Willoughby DA (eds). Inflammation Protocols; Methods In Molecular Biology, vol. 225 Humana Press: New Jersey, pp 209–222.
63. Zarif A, Eiznhamer D, Callaghan C, Doria MI, Broutman L, Keshavarzian A (1996). The effect of a selective 5‐lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats. Inflammation 20: 217–227.
64. Zhang M, Thurmond RL, Dunford PJ (2007). The histamine H(4) receptor: a novel modulator of inflammatory and immune disorders. Pharmacol Ther 113: 594–606.
65. Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi P (1993). Effects of zileuton, a new 5‐lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 39: 150–156.